Sometimes a stock just needs a breather. That seems to be the case with Tvardi Therapeutics (TVRD), which saw its shares slide in Thursday's premarket session as investors appeared to cash in some chips after a wild ride. The stock had more than doubled since Tuesday following the release of positive Phase 1 data for its investigational therapy TTI-109.

So what's the big deal about TTI-109? It's a phosphate prodrug of Tvardi's lead candidate TTI-101, designed to improve drug delivery and tolerability while keeping the same mechanism of action. The Phase 1 study showed that TTI-109 converts to TTI-101 within two hours and achieves nearly identical plasma exposure at molar-equivalent doses. That's exactly what you want from a prodrug strategy — it works as intended.

The company also reported that the study confirmed meaningful reductions in disease-relevant STAT3-driven immune cell populations. STAT3 is a protein that, when overactive, is linked to a bunch of inflammatory and fibrotic diseases. Tvardi plans to push TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, assuming it can rustle up the funding.

Now, let's talk technicals. Tvardi shares are currently trading at $4.56, well above their 20-day simple moving average of $2.53 — that's a bullish short-term signal. But zoom out, and the stock is still 31.7% below its 200-day SMA of $6.60, so the long-term picture is less rosy. The Relative Strength Index (RSI) is at 77.04, which means the stock is in overbought territory. That often precedes a pullback, which is exactly what we're seeing today.

Key levels to watch: resistance at $6.00 (a psychological round number) and support at $4.00, where buyers have stepped in before.

Despite the premarket dip, analysts are still pretty high on Tvardi. The stock carries a Buy rating with an average price target of $8.00. Recent moves include Raymond James upgrading to Outperform with a $10 target on July 8, BTIG maintaining a Buy with a $15 forecast on July 7, and HC Wainwright initiating with a Buy and $9 target on June 8.

As of Thursday premarket, TVRD shares were down 8.20% at $4.59, according to market data.